Frovatriptan as a Transitional Therapy in Medication Overuse Headache

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2019-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will analyze the effectiveness of a medication called Frovatriptan, in the context of medication overuse headache (MOH). MOH is a headache that develops when pain-killers are taken frequently. The treatment is to stop the overuse of these pain-killers, but that can sometimes worsen the headache first before it gets better. We are testing Frovatriptan against placebo to see if it can help patients with this transition and avoid the worsening of the headache that can occur. We will also see if Frovatriptan can help in other ways, such as maintain patients free of medication overuse.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detoxification and Treatment of Subjects With Medication Overuse Headache

NCT00432549

Analgesic Rebound Headache

UNKNOWN PHASE4

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting

NCT00440232

Migraine

COMPLETED NA

Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?

NCT00159588

Headache

COMPLETED NA

A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine

NCT00821483

Migraine

COMPLETED PHASE3

Medication-overuse Headache: 4 Years Follow up

NCT00918671

Medication Overuse Headache

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single-centre, randomized, placebo-controlled trial is proposed to assess Frovatriptan as a transitional therapy in patients diagnosed with medication overuse headache. Currently, there are no proven transitional therapies to help patients get through the detoxification process. Frovatriptan has not been tested as a transitional therapy in the past. This study will compare Frovatriptan, taken over a 10 day transitional period, to placebo. The primary outcome of the study will be the mean headache intensity in the 10 day transitional period in the Frovatriptan group as compared to the placebo group. A number of secondary and exploratory outcomes will also be determined and further data collection will occur at 1, 2, and 3 month periods. The duration of the study for the participants will be 3 months, and they will be asked to keep detailed headache diaries during this time. Ten days of baseline headache diaries will also be performed before patients can enter the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medication Overuse Headache Analgesic Overuse Headache

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

10 days of treatment with placebo in a bid fashion that will look like the study medication.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1 tab po bid for 10 days

Frovatriptan

Frovatriptan 2.5 mg po bid for 10 days

Group Type EXPERIMENTAL

Frovatriptan

Intervention Type DRUG

2.5 mg po bid for 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Frovatriptan

2.5 mg po bid for 10 days

Intervention Type DRUG

Placebo

1 tab po bid for 10 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MOH diagnosed by IHS criteria
* Diagnosis of migraine (with or without aura) in past by IHS criteria
* If patients do not have a baseline diary, then a prospective diary for a 10-day period will be done to confirm medication overuse before study entry.
* Patients aged 18 to 65 years.
* Normal neurological examination.
* Patient is willing and able (in terms of capacity) to sign informed consent.
* Patient is able to understand and complete study protocol, including completion of headache diaries.
* Patient has a stable medical condition.

Exclusion Criteria

* Headache not meeting IHS criteria for MOH.
* Presence of hemiplegic, basilar, ophthalmoplegic migraine or migrainous infarction.
* Findings on history, neurological exam, or neuroimaging suggestive of secondary causes of headache.
* Post-whiplash or post-traumatic headaches.
* Contraindications to triptans (such as heart disease, peripheral vascular disease or uncontrolled hypertension) or previous serious side effects/intolerance.
* Major psychiatric conditions (such as major depression, bipolar disorder, schizophrenia, addiction), either diagnosed by a physician or positive on standard clinic assessment tools (e.g. BDI questionnaire).
* Major medical conditions or treatments that may interfere with the patient's ability to participate in the study, such as dementia, advanced or terminal cancer, chemotherapy, etc.
* Patient is pregnant, breastfeeding, or is expecting to conceive within the time period of the study. Pregnancy will be determined using a urine test.
* Women of childbearing potential who are not using a reliable method of contraception.
* Patient is a recent user of illicit/recreational drugs or plans to use illicit drugs during the study time period.
* Patient has a recent history of alcohol abuse or dependence, or plans to abuse alcohol during the study duration.
* Patient is unlikely to comply with the study protocol, keep diaries and appointments, or does not have a fixed telephone or address.
* Patient is enrolled in another study or trial that may interfere with their participation or the results of this study.
* Patients with greater than 30% of their data missing during the ten days of baseline diary data collection.
* Patients with mean headache intensities of less than 3 (from a pain scale of 0 to 10, where 0=no pain and 10=pain as bad as possible) during the 10-day baseline period.
* Patients with ongoing Botox treatments or those who have received Botox in the last 4 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No